<DOC>
	<DOC>NCT01703455</DOC>
	<brief_summary>This is a single agent, prospective, open-label, monocenter, phase II trial of sorafenib in patients with recurrent and/or metastatic salivary gland carcinoma. This trial will be conducted with the primary aim to determine the response rate (CR+PR) according to the RECIST criteria. Response rate according to CHOI criteria, correlation between CHOI criteria and outcome, disease Control Rate (DCR) and acute toxicity will be evaluated as secondary objectives.</brief_summary>
	<brief_title>Activity of Sorafenib in Salivary Gland Cancer</brief_title>
	<detailed_description />
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Histologically proven relapsed and/or metastatic salivary gland cancer for which potentially curative options such as surgery or radiotherapy are not indicated One target lesion measurable by CTscan or MRI according to RECIST criteria Age + 18 years ECOG 0 or 1 Adequate bone marrow, liver and renal function Signed written informed consent Symptomatic metastatic brain or meningeal tumors History of cardiac disease such as congestive heart failure&gt;NYHA class 2 Active CAD Cardiac arrhythmias requiring antiarrhythmic therapy or uncontrolled hypertension Pregnant or breastfeeding patient Patients with evidence or history of bleeding diathesis Patients undergoing renal dialysis Patients unable to swallow oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Salivary gland cancer metastatic disease recurrent disease clinical trial</keyword>
</DOC>